On December 19, 2023, Xu Bin, Secretary of the Party Group and Director of the Sichuan Provincial Health Commission, along with Deputy Director Xinhua Li and Second-level Inspector Li Cao, Xiaotao Yang, Secretary of the Party Group and Director of the Chengdu Municipal Health Commission, party member Zhigang Liu, Huan Liu, Member of the Party Committee of the Chengdu High-tech Zone Working Committee and Deputy Director of the Management Committee, Jun Tian, Secretary of the Party Group and Director of the Chengdu High-tech Zone Health Bureau, as well as leaders and experts from the Chengdu High-tech Zone Bio-industry Bureau, Health Bureau, and relevant departments, visited Chengdu Shiliankangjian Biotechnology Co., Ltd. for research.

Professor Weidong Tian, founder and chief scientist of Chengdu Shiliankangjian Biotechnology Co., Ltd., and Yingfeng Tang, Vice General Manager and also General Manager of Sichuan Cell Bank Co., Ltd., along with other company executives, hosted and engaged in discussions. They accompanied the leaders and experts on a tour of Chengdu Shiliankangjian Biotechnology Co., Ltd., Sichuan Cell Bank, and the Sichuan Province Tianfu Cell Quality Testing and Evaluation Center. They provided a comprehensive introduction to the industrial layout of Chengdu Shiliankangjian Biotechnology Co., Ltd., focusing on "one bank, two centers, three platforms, and four systems."

The leaders and experts participating in the research highly praised the platform construction achievements of Chengdu Shiliankangjian Biotechnology Co., Ltd. They provided guidance on the company's innovative development in life sciences and biotechnology, focusing on major clinical treatments and the entire lifecycle health needs, thereby promoting high-quality development of the health industry.

Shiliankangjian, led by Professor Weidong Tian, Chief Scientist of the national 973 Project, was jointly funded by West China Hospital, West China Stomatology Hospital, West China Second Hospital, Chengdu High-tech Zone Government, and Shanghai Pharmaceuticals Group, a top 50 global pharmaceutical company. Leveraging the century-old clinical strength of West China Medical School and national-level scientific research platforms, they have constructed an integrated development model of "medicine, education, research, and production," establishing a comprehensive one-stop cell industry platform.

       Shiliankangjian includes Sichuan Cell Bank Co., Ltd. and Sichuan Tianfu Cell Quality Testing and Evaluation Center Co., Ltd. They have built a biobank capable of storing millions of human samples, including over a dozen types of research and clinical-grade cells. They have obtained approval from the Ministry of Science and Technology of China for the preservation of Chinese human genetic resources, making it the only third-party cell resource bank in Southwest China with national-level qualification. They also have a high-level GMP standard cell drug production facility, meeting the standards of a core production area within a B-level overall background. They have established a complete set of cell production operations based on GMP/ISO standards and a GMP quality management system for cell drugs, ensuring quality control in the aspects of personnel, machines, materials, methods, and environment. They have obtained a "Drug Production License" from the Sichuan Provincial Drug Administration and operate a third-party quality testing and evaluation center capable of providing over a hundred cell testing services. Based on the foundation of "one bank, two centers," they have established a public technology platform for stem cell technology research and application, providing cell technology and cell drug transformation services to research institutions and enterprises.